Life Healthcare Group Holdings Limited (LTGHF)
- Previous Close
0.0000 - Open
1.0100 - Bid 0.6765 x --
- Ask 0.8183 x --
- Day's Range
1.0100 - 1.0100 - 52 Week Range
0.5350 - 1.0100 - Volume
12,005 - Avg. Volume
2 - Market Cap (intraday)
1.181B - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
11.70 - EPS (TTM)
0.0700 - Earnings Date May 22, 2025
- Forward Dividend & Yield 0.03 (3.39%)
- Ex-Dividend Date Jan 8, 2025
- 1y Target Est
--
Life Healthcare Group Holdings Limited, an investment holding company, operates as a private healthcare company in Southern Africa, the United Kingdom, Europe, the United States, and internationally. The company operates acute hospitals. It also offers mental health, acute rehabilitation, renal dialysis, oncology, and imaging services. In addition, the company provides long-term services for patients requiring frail care, chronic mental healthcare, and substance abuse support; wellness programs, and occupational and primary healthcare to corporate and institutional clients; and contracted on-site occupational, primary, and emergency healthcare services to large private and public employees. Further, the company develops and commercializes molecular imaging agents for use in positron emission computerized tomography diagnostics. The company was formerly known as Afrox Healthcare Limited and changed its name to Life Healthcare Group Holdings Limited in January 2005. Life Healthcare Group Holdings Limited was founded in 1983 and is headquartered in Johannesburg, South Africa.
www.lifehealthcare.co.za--
Full Time Employees
September 30
Fiscal Year Ends
Sector
Industry
Recent News: LTGHF
View MorePerformance Overview: LTGHF
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is All Share Index (^J203.JO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LTGHF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LTGHF
View MoreValuation Measures
Market Cap
1.18B
Enterprise Value
1.29B
Trailing P/E
11.07
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.87
Price/Book (mrq)
1.75
Enterprise Value/Revenue
0.94
Enterprise Value/EBITDA
5.40
Financial Highlights
Profitability and Income Statement
Profit Margin
18.72%
Return on Assets (ttm)
5.36%
Return on Equity (ttm)
12.58%
Revenue (ttm)
25.79B
Net Income Avi to Common (ttm)
1.99B
Diluted EPS (ttm)
0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
2.46B
Total Debt/Equity (mrq)
32.71%
Levered Free Cash Flow (ttm)
20.5B